family with sequence similarity 13 member BGenealiases: ARHGAP49 · C5orf5 · FAM13B1 · KHCHP · N61
Q-omics provides the consensus-scored FAM13B profile across patient tissues and cancer cell-line models. FAM13B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM13B is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, FAM13B RNA expression shows 21,550 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where FAM13B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM13B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM13B survival associations across molecular data types. FAM13B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM13B RNA expression–survival associations across cancer types. High FAM13B expression shows unfavorable associations in LGG and ESCA, but favorable associations in KIRC, LUAD, HNSC and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM13B RNA expression.
This table summarizes FAM13B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM13B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM13B shows lower tumor expression in THCA, COAD, LUAD, LUSC and BLCA and higher tumor expression in LIHC. The THCA box plot shows higher FAM13B RNA expression in normal versus tumor tissue (log2 FC = −0.805, t-test p < 0.001).
This table shows molecular features associated with FAM13B in patient tissues and cancer cell lines. In patient samples, FAM13B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM13B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
